Skip to content
Menu

Travere Therapeutics, Inc. TVTX

Full chart Compare
Set alert

Price alert · TVTX

All alert types
50.51 USD -0.59 (-1.16%)

As ofNov 18, 2026, 2:36 PM EST

49.81 Day range 51.40
22.59 52-week range 68.73
YTD
+32.18%
1 year
+40.29%
Market cap
4.85B
Revenue (ttm)
651.03M
Profit margin
-18.66%
EPS (ttm)
-1.67
Shares out
95.99M
Forward P/E
9.43
YTD return
+32.18%
1-year return
+40.29%
50-day average
55.62
200-day average
47.78
Volume
399.85K
Avg volume
1.82M
Open
51.06
Previous close
51.10
Day's range
49.81 – 51.40
52-week range
22.59 – 68.73
Beta
1.12
Analysts
Strong Buy
Price target
73.43 (+45.4%)
Earnings date
Feb 18, 2027

5D -0.79 (-1.53%)

5052WedThuFriMonTue50.91

Key statistics

Enterprise value
4.92B
Price / sales
7.53
Price / book
216.53
Revenue growth
36.20%
Free cash flow
-64.79M
Total cash
471.82M
Total debt
616.16M
Return on equity
-321.22%
Short % of float
12.90%

Fundamental scorecard

6 of 25 checks passed on TVTX’s reported financials

ValueGrowthProfitabilityHealthDividend

6of 25 checks passed

  • Value 0 of 5
  • Growth 2 of 5
  • Profitability 1 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
TVTX Revenue — quarterly 224.56M
TVTX Net income — quarterly -52.34M
TVTX EPS — quarterly -0.55

Earnings

TVTX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 18, 2027Dec 30, 20260.4397———
Nov 2, 2026Sep 30, 2026-0.05545-0.55-0.49-891.88%
Aug 4, 2026Jun 30, 2026-0.13465-0.37-0.24-174.79%
May 4, 2026Mar 31, 2026-0.30-0.39-0.09-30.00%
Feb 19, 2026Dec 31, 20250.030.030.000.00%
Oct 30, 2025Sep 30, 2025-0.310.28+0.59+190.32%

Upgrades / downgrades

TVTX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 6, 2026JP MorganmainOverweightOverweight
Nov 5, 2026Leerink PartnersmainOutperformOutperform
Nov 4, 2026Canaccord GenuitymainBuyBuy
Nov 4, 2026GuggenheimmainBuyBuy
Sep 24, 2026GuggenheimmainBuyBuy
Sep 22, 2026WedbushreitOutperformOutperform

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
travere.com

News

Your note

Sign in to keep a note on TVTX — it syncs with the Stock Master app.

Institution ownership

TVTX institution ownership
Holder% heldSharesValueReported
Janus Henderson Group Ltd.12.39%11,891,480607.65MSep 29, 2026
Blackrock Inc.9.04%8,673,231443.20MSep 29, 2026
FMR, LLC6.11%5,867,919299.85MSep 29, 2026
Bank of America Corporation6.07%5,824,254297.62MSep 29, 2026
State Street Corporation4.57%4,387,309224.19MSep 29, 2026
Vanguard Capital Management LLC4.37%4,192,887214.26MSep 29, 2026

Fund ownership

TVTX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund3.07%2,947,890150.64MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.41%2,310,625118.07MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.32%2,231,509114.03MSep 29, 2026
Delaware Group Equity Funds V-Nomura Small Cap Core Fund1.63%1,569,28680.19MAug 30, 2026
Vanguard Explorer Fund1.49%1,431,33173.14MJul 30, 2026
JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund1.43%1,376,98670.36MSep 29, 2026